Advertisement

Tumor Biology

, Volume 33, Issue 6, pp 2143–2150 | Cite as

Effects of microvascular density on primary pulmonary non-Hodgkin’s lymphoma (PPL)

  • Maopeng Yang
  • Shu Zhao
  • Xaiosan Zhang
  • Xiaohong Wang
  • Minghui Zhang
  • Yan Wang
  • Qingyuan Zhang
Research Article

Abstract

This study aims to analyze 30 cases of primary pulmonary lymphoma (PPL) including treatment as well as follow-up information during the past 10 years and to investigate the correlation between microvessel density (MVD) and survival in patients with PPL. We reviewed all patients from October 2000 to October 2010. Patient demographics such as survival, recurrence, time to follow-up, and treatment mode were recorded. We also assessed MVD in the pretreated pulmonary lymphoma tissues of 30 previously untreated patients using α-CD34 immunohistochemical staining. The median age of the 30 patients was 46.9 years. With a median follow-up of 4.3 years (range, 2 to 10 years), the 5-year overall survival (OS) rate was 57 % and progression-free survival (PFS) was 44 %. High MVD, elevated serum lactate dehydrogenase (LDH), and B symptoms was significantly correlated with clinical features and shorter PFS (P MVD = 0.021, P LDH = 0.023, and P B symptoms = 0.005) and OS (P MVD = 0.028, P LDH = 0.032, and P B symptoms = 0.001). Application of surgical treatment improved the PFS (P = 0.024) and OS (P = 0.028) of patients with stage IE disease (patients who were nodal negative). The patient’s stage predicted the outcome and guides the use of treatments. Patients with high MVD measured in the microenvironment had worse PFS/OS than those with low MVD expression. Patients who had B symptoms or elevated serum LDH had poor prognosis. Patients with lymph node involvement (stage IIE or greater) had poor prognosis.

Keywords

Primary pulmonary lymphoma Microvessel density Prognosis Survival analysis 

Notes

Acknowledgments

I confirm that the article is my original work, that it has not been published elsewhere, and that it has not been submitted simultaneously for publication elsewhere. I also confirm that the article is free of plagiarism, is accurate, and does not infringe on anyone’s copyright or other rights. As corresponding author, I hereby acknowledge the above and declare that all relevant associations, which may pose a conflict of interest, have been cited on the first page of the manuscript. Work on this article was finished in the Oncobiology Key Lab of Heilongjiang Common Institution of Higher Learning.

Conflicts of interest

None.

References

  1. 1.
    Borie R, Wislez M, Thabut G, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 2009;34:1408–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disease in one third of 158 patients analyzed. Blood. 2000;95:802–6.PubMedGoogle Scholar
  3. 3.
    Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489–95.PubMedCrossRefGoogle Scholar
  4. 4.
    Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000;69:993–7. doi: 10.1016/S0003-4975(99)01535-0.PubMedCrossRefGoogle Scholar
  5. 5.
    Kurtin PJ, Myers JL, Adlakha H, Strickler JG, Lohse C, Pankratz VS, et al. Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type. Am J Surg Pathol. 2001;25:997–1008. doi: 10.1097/00000478-200108000-00003.PubMedCrossRefGoogle Scholar
  6. 6.
    Pagani M, Antico A, et al. Primary pulmonary high grade non-Hodgkin’s lymphoma in an elderly patient. A case report. Tumori. 2007;93:622–4.PubMedGoogle Scholar
  7. 7.
    Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J. 2002;20:750–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Zinzani PL, Tani M, Gabriele A, et al. Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients. Leuk Lymphoma. 2003;44:821–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Ahmed S, Kussick SJ, Siddiqui AK, Bhuiya TA, Khan A, Sarewitz S, et al. Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer. 2004;40:1320–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Kim JH, Lee SH, Park J, Kim HY, Lee SI, Park JO, et al. Primary pulmonary non-Hodgkin’s lymphoma. Jpn J Clin Oncol. 2004;34:510–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Brian B, Graham MD, Douglas J. Primary pulmonary lymphoma. Ann Thorac Surg. 2005;80:1248–53.CrossRefGoogle Scholar
  12. 12.
    Gratzinger D, Zhao S, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest. 2008;88:38–47.PubMedCrossRefGoogle Scholar
  13. 13.
    Gratzinger D, Zhao S, Marinelli RJ, et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol. 2007;170:1362–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Isaacson PG, Piris MA, et al. Extranodal marginal zone B-cell lymphoma of maucosa-associated lymphoid tissue (MALT lymphoma). In: Press I, Jaffe ES, Harris NL, et al., editors. Pathology and genetics: tumours of haematopoietic tissues. Lyon: World Health Organization Classification of Tumours; 2001. p. 157–60.Google Scholar
  15. 15.
    Habermann TM, Ryu JH, Inwards DJ, Kurtin PJ. Primary pulmonary lymphoma. Semin Oncol. 1999;26:307–15.PubMedGoogle Scholar
  16. 16.
    Fiche M, Caprons F, Berger F, Galateau F, Cordier JF, Loire R, et al. Primary pulmonary non-Hodgkin’s lymphoma. Histopathology. 1995;26:529–37.PubMedCrossRefGoogle Scholar
  17. 17.
    Kim JH, Lee S-H, Park J, et al. Primary pulmonary non-Hodgkin’s lymphoma. Jpn J Clin Oncol. 2004;34(9):510–4. doi: 10.1093/jjco/hyh095.PubMedCrossRefGoogle Scholar
  18. 18.
    Isaacson PG, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer. 1984;53:2515–24.PubMedCrossRefGoogle Scholar
  19. 19.
    Yoshino T, Ichimura K, Mannami T, et al. Multiple organ mucosa-associated lymphoid tissue lymphomas often involve the intestine. Cancer. 2001;91:346–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000;69:993–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Tamura A, Komatsu H, Yanai N, et al. Primary pulmonary lymphoma: relationship between clinical features and pathologic findings in 24 cases. The Japan national chest hospital study group for lung cancer. Jpn J Clin Oncol. 1995;25:140–52.PubMedGoogle Scholar
  22. 22.
    Kim JH, Lee SH, Park J, Kim HY, Lee SI, Park JO, et al. Primary pulmonary non-Hodgkin’s lymphoma. Jpn J Clin Oncol. 2004;34:510–4. doi: 10.1093/jjco/hyh095.PubMedCrossRefGoogle Scholar
  23. 23.
    Hu YH, Hsiao L-T, Yang C-F, et al. Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin’s lymphoma: the single-institute experience in Taiwan. Ann Hematol. 2009;88:839–46.PubMedCrossRefGoogle Scholar
  24. 24.
    Ray P, Antoine M, Mary-Krause M, Lebrette MG, Wislez M, Duvivier C, et al. AIDS-related primary pulmonary lymphoma. Am J Respir Crit Care Med. 1998;158:1221–9.PubMedGoogle Scholar
  25. 25.
    Li G, Hansmann M-L, Zwingers T, Lennert K. Primary lymphomas of the lung: morphological, immunohistochemical and clinical features. Histopathology. 1990;16:519–31.PubMedCrossRefGoogle Scholar
  26. 26.
    Wannesson L, Cavalli F, Zucca E. Primary pulmonary lymphoma: current status. Clin Lymphoma Myeloma. 2005;6:220–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Hu YH, Liu CY, Chiu CH, Hsiao LT. Successful treatment of elderly advanced lymphomatoid granulomatosis with rituximab-CVP combination therapy. Eur J Haematol. 2007;78:176–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000;69:993–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Vanden Eynden F, Fadel E, de Perrot M, et al. Role of surgery in the treatment of primary pulmonary B-cell lymphoma. Ann Thorac Surg. 2007;83:236–40.CrossRefGoogle Scholar
  30. 30.
    Tamura A, Komatsu H, Yanai N, et al. Primary pulmonary lymphoma: relationship between clinical features and pathologic findings in 24 cases, The Japan National Chest Hospital Study Group for Lung Cancer. Jpn J Clin Oncol. 1995;25:140–52.PubMedGoogle Scholar
  31. 31.
    Ferraro P, Trastek VF, et al. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000;69:993–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Vanden Eynden F, Fadel E, de Perrot M, et al. Role of surgery in the treatment of primary pulmonary B-cell lymphoma. Ann Thorac Surg. 2007;83:236–40.CrossRefGoogle Scholar
  33. 33.
    Wannesson L, Cavalli F, Zucca E. Primary pulmonary lymphoma: current status. Clin Lymphoma Myeloma. 2005;6:220–7. doi: 10.3816/CLM.2005.n.049.PubMedCrossRefGoogle Scholar
  34. 34.
    Kurtin PJ, Myers JL, Adlakha H, Strickler JG, et al. Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type. Am J Surg Pathol. 2001;25:997–1008. doi: 10.1097/00000478-200108000-00003.PubMedCrossRefGoogle Scholar
  35. 35.
    Zinzani PL, Tani M, Gabriele A, Poletti V, Stefoni V, Alinari L, et al. Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients. Leuk Lymphoma. 2003;44:821–4. doi: 10.1080/1042819031000067972.PubMedCrossRefGoogle Scholar
  36. 36.
    Ahmed S, Kussick SJ, Siddiqui AK, et al. Bronchialassociated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer. 2004;40:1320–6. doi: 10.1016/j.ejca.2004.02.006.PubMedCrossRefGoogle Scholar
  37. 37.
    Lewis ER, Caskey CI, Fishman EK. Lymphoma of the lung: CT findings in 31 patients. Am J Roentgenol. 1991;156:711–4.Google Scholar
  38. 38.
    Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489–95. doi: 10.1182/blood-2002-04-1279.PubMedCrossRefGoogle Scholar
  39. 39.
    Bae YA, Lee KS, Han J, Ko YH, Kim BT, Chung MJ, et al. Marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue: imaging findings in 21 patients. Chest. 2008;133:433–40. doi: 10.1378/chest.07-1956.PubMedCrossRefGoogle Scholar
  40. 40.
    Bolat F, Kayaselcuk F, Nursal TZ, et al. Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res. 2006;25:365–72.PubMedGoogle Scholar
  41. 41.
    Tsutsui S, Yasuda K, Suzuki K, et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005;14:425–31.PubMedGoogle Scholar
  42. 42.
    Kumar S, Gertz MA, Dispenzieri A, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004;34:235–9.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.Department of Medical OncologyThe Third Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations